Improvement of the efficacy and safety of oral methoxsalen photochemotherapy.
To improve efficacy and safety of psoralen plus UV radiation at 320-400 nm (PUVA), investigators designed different therapeutic approaches. Our goals are to minimize the acute risks and lower the long-term hazards. Some of these therapeutic approaches focus on dosimetry and intensity of PUVA and some on combining PUVA with other therapeutic modalities. Both approaches try to minimize the total number of treatments and to decrease the amount of UVA radiation delivered to the patient and, as a result, decrease the total skin insult.
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000875:Anthralin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D011701:PUVA Therapy / Q000009:adverse effects; D010778:Photochemotherapy / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy*; D012176:Retinoids / Q000008:administration & dosage; D013638:Tars / Q000008:administration & dosage
D000305:Adrenal Cortex Hormones; D012176:Retinoids; D013638:Tars; D000875:Anthralin; D008727:Methotrexate